PMGC Holdings ELAB
NASDAQ ELAB
$4.57 -0.05 (-1.08%)
As of: Sep 10, 2026 · 11:00 AM EDT

PMGC Holdings (ELAB) Work In Process (2023 - 2026)

PMGC Holdings' (ELAB) quarterly Work In Process came in at $325112.0 in Q2 2026, up 287.74% quarter-over-quarter from $83849.0 in Q1 2026.

Analysis

PMGC Holdings (ELAB) Work In Process (2023 - 2026) Analysis & Trends

PMGC Holdings has disclosed Work In Process across 3 years of filings, most recently posting $325112.0 for Q2 2026.

  • In Q2 2026, Work In Process changed N/A year-over-year to $325112.0; the TTM figure through Jun 2026 stood at $325112.0 (changed N/A YoY), while the FY2023 annual figure was $147906.0, changed N/A from the prior year.
  • Work In Process came in at $325112.0 for Q2 2026 at PMGC Holdings, up from $83849.0 in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $325112.0 in Q2 2026 to a low of $83849.0 in Q1 2026.
  • Average Work In Process over 3 years is $236640.0, with a median of $286446.5 recorded in 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 207.11 Bn 193.12 Bn 7.24 Bn
2 Gilead Sciences 178.91 Bn 175.73 Bn 6.22 Bn
3 Vertex Pharmaceuticals 131.35 Bn 123.50 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.84 Bn 73.85 Bn 3.93 Bn
5 Argenx Se 61.06 Bn 55.87 Bn 1.37 Bn
6 Moderna 53.08 Bn 47.94 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.32 Bn 30.01 Bn 992.69 Mn
8 Biogen 31.70 Bn 30.41 Bn 1.96 Bn
9 Roivant Sciences 29.48 Bn 29.48 Bn 1.16 Mn
10 PMGC Holdings 2.23 Mn -16.56 Mn 385,691.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 325,112.00
Mar 31, 2026 83,849.00
Sep 30, 2024 289,113.00
Jun 30, 2024 290,080.00
Mar 31, 2024 283,780.00
Dec 31, 2023 147,906.00